42494-73-5
物理化学性质
| 储存条件 | -20°C |
| 溶解度 | 在水中的溶解度为20mg/mL，澄清 |
| 形态 | 黄色固体 |
| 颜色 | 淡黄色至深黄色 |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H315-H319-H335 |
| 防范说明 | P261-P264-P271-P280-P302+P352-P305+P351+P338 |
| 危险品标志 | Xi |
| 危险类别码 | 36/37/38 |
| 安全说明 | 36/37/39 |
| WGK Germany | 3 |
常见问题列表
IC50: 38 nM (PTEN), 343 nM (PTP-β) and 920 nM (PTP-1B)
Parasite
Leishmania
Apoptosis
bpV(phen) (5 μM; 24.5 hours; H9c2 cells) treatment causes a further decrease of cell viability in H/R-injured H9c2 cells.
bpV(phen) (5 μM; 24.5 hours; H9c2 cells) treatment increases the apoptosis of H/R-injured H9c2 cells.
bpV(phen) (5 μM; 24.5 hours; H9c2 cells) treatment significantly promotes the accumulation of cytoplasmic Cytochrome C in H/R-injured H9c2 cells.
After stimulation of bpV(phen), PTEN-induced putative kinase protein 1 (PINK1)/Parkin-mediated mitophagy is inhibited.
bpV(phen) is an insulin-mimetic agent following insulin-receptor tyrosine kinase hyperphosphorylation and activation.
Cell Viability Assay
| Cell Line: | Hypoxia/reoxygenation (H/R)-injured H9c2 cells |
| Concentration: | 5 μM |
| Incubation Time: | 24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes) |
| Result: | Caused a further decrease of cell viability. |
Apoptosis Analysis
| Cell Line: | Hypoxia/reoxygenation (H/R)-injured H9c2 cells |
| Concentration: | 5 μM |
| Incubation Time: | 24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes) |
| Result: | Increased the apoptosis of H/R-injured H9c2 cells. |
Western Blot Analysis
| Cell Line: | Hypoxia/reoxygenation (H/R)-injured H9c2 cells |
| Concentration: | 5 μM |
| Incubation Time: | 24.5 hours (hypoxia for 24 h; reoxygenation for 30 minutes) |
| Result: | Showed an increased release of Cytochrome C. |
bpV(phen) (5 mg/kg; intraperitoneal injection; daily; for 38 days; male BALB/c nude (nu/nu) athymic mice) treatment causes a significant reduction in average tumor volume.
| Animal Model: | Male BALB/c nude (nu/nu) athymic mice (6-7 weeks old) injected with PC-3 cells |
| Dosage: | 5 mg/kg |
| Administration: | Intraperitoneal injection; daily; for 38 days |
| Result: | Caused a significant reduction in average tumor volume. |